Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Alliance completes enrollment in phase II/III trial of LiquiVent

Dec. 15, 2000

Dual Tx synthase and 5-LO inhibitors synthesized at Nikken

Dec. 14, 2000

New Claritin formulation receives FDA marketing approval

Dec. 14, 2000

Kaken presents dual LTD4 and TxA2 antagonist with promising antiasthmatic profile

Dec. 13, 2000

Bronchial effects of prostanoid DP antagonist reported at Japanese Society of Allergology meeting

Dec. 13, 2000

Health Canada approves Asmanex Twisthaler for treatment of asthma

Dec. 12, 2000

Mid-November launch in Japan for Allegra

Dec. 7, 2000

Synthesis and biological activity of Pfizer's new PDE4 inhibitors

Dec. 7, 2000

Potential new agents for asthma selectively inhibit human PDE4

Dec. 1, 2000

Active components of traditional Indonesian asthma medicine identified

Dec. 1, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...